WO2002021138A3 - Die m30-genfamilie und ihre verwendung - Google Patents

Die m30-genfamilie und ihre verwendung Download PDF

Info

Publication number
WO2002021138A3
WO2002021138A3 PCT/EP2001/010366 EP0110366W WO0221138A3 WO 2002021138 A3 WO2002021138 A3 WO 2002021138A3 EP 0110366 W EP0110366 W EP 0110366W WO 0221138 A3 WO0221138 A3 WO 0221138A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
utilization
relates
ligands
over
Prior art date
Application number
PCT/EP2001/010366
Other languages
English (en)
French (fr)
Other versions
WO2002021138A2 (de
Inventor
Armin Schneider
Holger Hiemisch
Moritz Rossner
Matthias Klugmann
Jomana Naim
Gisela Eisenhardt
Rohini Kuner
Anthony Lanahan
Paul Worley
Daniela Spielvogel
Sigrid Scheek
Original Assignee
Axaron Bioscience Ag
Armin Schneider
Holger Hiemisch
Moritz Rossner
Matthias Klugmann
Jomana Naim
Gisela Eisenhardt
Rohini Kuner
Anthony Lanahan
Paul Worley
Daniela Spielvogel
Sigrid Scheek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axaron Bioscience Ag, Armin Schneider, Holger Hiemisch, Moritz Rossner, Matthias Klugmann, Jomana Naim, Gisela Eisenhardt, Rohini Kuner, Anthony Lanahan, Paul Worley, Daniela Spielvogel, Sigrid Scheek filed Critical Axaron Bioscience Ag
Priority to AU2002214970A priority Critical patent/AU2002214970A1/en
Publication of WO2002021138A2 publication Critical patent/WO2002021138A2/de
Publication of WO2002021138A3 publication Critical patent/WO2002021138A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung betrifft unter anderem ein Verfahren zur Diagnose neurodegenerativer Erkrankungen, bei dem die Konzentration eines Proteins, das Ähnlichkeiten mit dem Protein Pellino besitzt, oder eines Säugetier-Homologes dieses Proteins oder eines Muteins dieses Proteins, das über einen Bereich von 50 Aminosäuren seiner Aminosäuresequenz eine Sequenzidentität mit einer der Sequenzen von über 60 % aufweist, in einer Körperprobe bestimmt wird. Weiterhin betrifft die Erfindung die Verwendung von Liganden, die an M30 und seine Homologen binden, sowie die Verwendung von funktionalen Inhibitoren zur Herstellung eines Arzneimittel zur Therapie von neurodegenerativen Erkrankungen. Desweiteren betrifft die Erfindung ein Screening-Verfahren zur Identifikation und/oder zur Charakterisierung von funktionalen Inhibitoren und/oder von Liganden von M30 oder einem Homologen von M30.
PCT/EP2001/010366 2000-09-07 2001-09-07 Die m30-genfamilie und ihre verwendung WO2002021138A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002214970A AU2002214970A1 (en) 2000-09-07 2001-09-07 The m30 gene family and the utilization thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65747900A 2000-09-07 2000-09-07
US09/657,479 2000-09-07

Publications (2)

Publication Number Publication Date
WO2002021138A2 WO2002021138A2 (de) 2002-03-14
WO2002021138A3 true WO2002021138A3 (de) 2003-03-20

Family

ID=24637341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010366 WO2002021138A2 (de) 2000-09-07 2001-09-07 Die m30-genfamilie und ihre verwendung

Country Status (2)

Country Link
AU (1) AU2002214970A1 (de)
WO (1) WO2002021138A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250507B2 (en) 2000-04-28 2007-07-31 Immunex Corporation Inhibitory Pellino nucleic acids
US6703487B2 (en) 2000-04-28 2004-03-09 Immunex Corporation Human pellino polypeptides
AU2002246922A1 (en) * 2001-01-02 2002-08-06 Tularik Inc. Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
JP5832534B2 (ja) * 2010-07-28 2015-12-16 アボット ゲーエムベーハー ウント コー． カーゲー 虚血性脳卒中を検出する方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] XP002217750, retrieved from EBI Database accession no. AP002748 *
DATABASE SWALL [online] XP002217749, retrieved from EBI Database accession no. O77237 *
KRAMER GERO ET AL: "Determination of apoptotic activity in the sera of patients with hormone refractory prostate cancer by a novel M30 apoptosis assay.", EUROPEAN UROLOGY, vol. 39, no. Suppl. 5, March 2001 (2001-03-01), XVIth Congress of the European Association of Urology;Geneva, Switzerland; April 07-10, 2001, pages 80, XP009000127, ISSN: 0302-2838 *
LINDER S ET AL: "The M30 antibody can be used to quantitate apoptosis in breast cancer cell extracts and culture supernatants.", TUMOR BIOLOGY, vol. 21, no. Supplement 1, September 2000 (2000-09-01), 28th Meeting of the International Society for Oncodevelopmental Biology and Medicine;Munich, Germany; September 08-13, 2000, pages 30, XP001105832, ISSN: 1010-4283 *

Also Published As

Publication number Publication date
AU2002214970A1 (en) 2002-03-22
WO2002021138A2 (de) 2002-03-14

Similar Documents

Publication Publication Date Title
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
WO1995015331B1 (en) SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS PRESENT IN HUMAN t(2;5) LYMPHOMA, METHODS OF DETECTION AND USES THEREOF
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
WO2001055364A8 (en) Nucleic acids, proteins, and antibodies
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
WO1997008314A3 (en) Telomere repeat binding factor and diagnostic and therapeutic use thereof
DE60025008D1 (de) Bestimmung von adrenomedullin-bindenden proteinen
ATE440860T1 (de) An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen
DE60129239D1 (de) Kit und verfahren zur bestimmung von protein esm-1
WO2002021138A3 (de) Die m30-genfamilie und ihre verwendung
ATE190318T1 (de) Pcna bindende substanz
WO2002026930A3 (en) Nucleic acids, proteins, and antibodies
ATE517629T1 (de) Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
DE69927668D1 (de) Massenfingerabdrucken und seiner verwendung zur identifizierung von protein-affinitätsliganden
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
DE60121735D1 (de) Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen
WO1999055885A3 (en) Novel serine protease capable of selective cleavage of insulin-like growth factor binding protein
Li et al. A simple and rapid method for isolating small myotoxins from rattlesnake venoms
SZIEGOLEIT et al. Further studies on human cholesterol-binding pancreatic protease/elastase 1. Immunological detection of analogous enzymes in several animal species and identification of the porcine-derived enzyme as protease E
WO2001036635A3 (en) Neurite outgrowth-promoting factor homologue and nucleic acids encoding same
WO2001085989A3 (de) Hyphenspezifische faktoren aus candida albicans
FR2782325B1 (fr) Procede d'identification de sequences polynucleotidiques et/ou des proteines correspondantes a partir d'un echantillon d'acides nucleiques
WO2001059114A3 (en) Tumor suppressor gene, p47ing3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP